[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Laikο General Hospital, Athens\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":44},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":12,"acronym":13,"eligibilityCriteria":14,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":26,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":5},"100613563",false,"NCT07268222","Metyrapone Versus Osilodrostat in Patients With Metabolic Autonomous Cortisol Secretion (MACS)","MOMACS","Inclusion Criteria:\n\n* Adults \\> 18 years old with MACS and unilateral or bilateral adrenal adenomas or hyperplasia (based on imaging)\n* 1 mg overnight dexamethasone suppression test (ODST): Cortisol levels at 8.00 am\\>1.8 μg\u002Fdl AND i) ACTH\\\u003C 15 pg\u002Fml OR ii) abnormal midnight salivary cortisol OR iii) Urinary free cortisol levels (UFC) \u002F24h ≥ of the UNL\n\nExclusion Criteria:\n\n* Abnormal liver enzymes\n* eGFR \\\u003C 40 ml\u002Fmin\u002F1.73 m3\n* Pseudocushing syndrome\n* Patients with any malignancy (active or past history), including ACC\n* ACTH-dependent Cushing syndrome (Cushing disease or ectopic Cushing syndrome)","ALL","18 Years",{"count":18,"type":19},150,"ESTIMATED","INTERVENTIONAL",[22],"PHASE4","This study will compare the efficacy and safety of the two 11β-hydroxylase inhibitors-metyrapone and osilodrostat-in patients with MACS.\n\nPrimary outcome To compare the efficacy (biochemical and clinical) of the two 11β-hydroxylase inhibitors (CYP11B1), metyrapone and osilodrostat, in patients with MACS not treated surgically (mainly bilateral adenomas or adrenal hyperplasias), as well as their side effects at time 0-, 3- and 6-months post-treatment.\n\nSecondary outcome To evaluate alterations in clinical parameters (Blood Pressure, Body Mass Index-BMI), metabolic parameters (fasting blood glucose, insulin, Hb1Ac, HOMA, OGTT and lipids levels) at time 0-, 3- and 6-month after the initiation of the treatment and their effect on Bone Mineral Density (BMD) 1 year post-diagnosis",[25],"Mild Autonomous Cortisol Secretion (MACS)",[27,28,29,30,31],"cortisol","Cushing","MACS","METYRAPONE","osilodrostat","RECRUITING","2025-12-03",{"date":35,"type":36},"2025-12-05","ACTUAL",{"date":38,"type":36},"2025-12-01",{"date":40,"type":19},"2027-11-25",{"name":42,"class":43},"Laikο General Hospital, Athens","OTHER",""]